The company continues to operate without revenue, reporting an operating loss of $6.3 million in 2026Q1 driven by intensive R&D expenditures of $4.1 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 28.27M | 27.57M | 19.85M | 22.9M | 19.23M | 12.89M | 10K |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 9.69M | 9.42M | 6.93M | 7.52M | 6.01M | 3.35M | 10K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 18.58M | 18.15M | 12.92M | 15.38M | 13.23M | 9.54M | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -28.27M | -27.57M | -19.85M | -22.9M | -19.23M | -12.89M | -10K |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -38.93% | 13.32% | -19.04% | -49.17% | -128840% | - |
| EBITDA | -28.27M | -27.57M | -19M | -22.9M | -19.23M | -12.89M | -10K |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | -34.48% | -45.13% | 17.02% | -19.04% | -49.17% | -128840% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -28.27M | -27.57M | -19M | -22.9M | -19.23M | -12.89M | -10K |
| Net Interest Income | -26K | 1.13M | 847K | 637K | 149K | 4K | 0 |
| Interest Income | -26K | 1.13M | 847K | 637K | 149K | 4K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.11M | 1.13M | 847K | 637K | 149K | 4K | 0 |
| Pretax Income | -27.16M | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -27.16M | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | -34.72% | -39.17% | 14.65% | -16.64% | -48.06% | -128800% | - |
| Net Income (Continuing) | -27.16M | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.16 | -1.32 | -1.11 | -1.43 | -1.51 | -1.09 | -0.00 |
| EPS Growth % | -18.02% | -18.92% | 22.38% | 5.3% | -38.53% | - | - |
| EPS (Basic) | - | -1.32 | -1.11 | -1.43 | -1.51 | -1.09 | -0.00 |
| Diluted Shares Outstanding | 23.41M | 21.81M | 17.11M | 15.56M | 12.66M | 12.72M | 12.72M |
| Basic Shares Outstanding | 23.41M | 21.81M | 17.11M | 15.56M | 12.66M | 12.72M | 12.72M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Clinical Trial Funding Dependency
As reported in recent financial statements, Nuvectis Pharma maintains a consistent expenditure profile, with R&D costs fluctuating between $2.7 million and $5.8 million per quarter, reflecting the intensive capital requirements inherent in advancing its NXP800 and NXP900 clinical-stage oncology pipeline through regulatory milestones.
The company's cost structure is entirely dominated by research and development, which serves as the primary engine for its future value proposition. Investors should monitor the volatility in these quarterly R&D figures, as they likely correlate with specific clinical trial phases and patient enrollment cycles rather than fixed operational overhead.
Based on the provided quarterly data, the company's net loss figures are frequently impacted by stock-based compensation, which reached $1.7 million in 2025Q2, suggesting that GAAP net income metrics may obscure the actual velocity of cash depletion required to sustain ongoing clinical development activities.
Analysts should prioritize cash burn analysis over reported net income to better gauge the company's runway. The presence of significant non-cash charges warrants further investigation into the firm's long-term compensation strategy and its potential impact on future equity dilution for existing shareholders.
According to the income statement history, Nuvectis Pharma operates without revenue, resulting in an operating loss that peaked at $7.8 million in 2025Q3, which highlights the company's total reliance on external capital markets to fund its fixed operating expenses and clinical trial obligations.
The absence of operating leverage is expected for a pre-revenue biotechnology firm, yet the persistent quarterly losses underscore the binary nature of the business model. Management's ability to maintain operational discipline while navigating these high fixed costs remains a critical factor for long-term viability.
While the company focuses on high-potential transcription factor inhibition, the lack of revenue and a reported cash position of $31.6 million suggest that the firm faces significant financing risk, as any delay in clinical data could necessitate dilutive equity raises to maintain operations.
Short-term observers may focus on the potential for share count expansion as a primary risk to equity value. The concentration of the pipeline into two primary assets means that any negative clinical outcome could lead to a rapid re-rating of the company's valuation, regardless of current cash levels.
Quick answers to the most common questions about buying NVCT stock.
For fiscal year 2025, Nuvectis Pharma, Inc. (NVCT) reported total revenue of $0.0M.
Nuvectis Pharma, Inc. (NVCT) reported a net loss of $26.4M for the fiscal year ending 2025.